<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710229</url>
  </required_header>
  <id_info>
    <org_study_id>EK 07-192-1007</org_study_id>
    <nct_id>NCT00710229</nct_id>
  </id_info>
  <brief_title>Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration</brief_title>
  <acronym>MANTA</acronym>
  <official_title>A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Krankenanstalt Rudolfstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krankenhaus der Barmherzigen Brüder Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsaugenklinik Salzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Hietzing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanuschkrankenhaus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in
      age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most
      important factor involved in this angiogenetic processes in the eye. This forms the basis for
      new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the
      FDA and one drug is used off-label. All these drugs are administered intravitreally. The
      present study aims to directly compare the effects ranibizumab and bevacizumab in a
      randomized controlled study in patients with neovascular AMD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of visual acuity over time</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events retinal thickness (OCT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 50 years

          -  Active primary or recurrent subfoveal lesion with CNV secondary to AMD

        Exclusion Criteria:

        Prior treatment with any intravitreal drug in the study eye

          -  Prior treatment with verteporfin photodynamic therapy in the study eye

          -  Prior treatment with systemic bevacizumab

          -  Prior treatment with any intravitreal durg or verteprofin photodynamic therapy in the
             nonstudy eye within the 3 moths before the study entry

          -  Laser photocoagulation within 1 month before study entry in the study eye

          -  Previous participation in any clinical trial within 1 month before the entry of the
             study

          -  Subfoveal fibrosis or atrophy in the study eye

          -  CNV in either of the two eye due to causes other than AMD such as histoplasmosis or
             pathologica myopia

          -  Retinal pigment epithelial tear involving the macula in the study eye

          -  Any concurrent intraocular condition in the study eye that could either require
             medical or surgical intervention during the 12 month study period or that could
             contribute to a loss of best corrected visual acuity over the 12 months study period
             (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). The decision on
             exclusion is to be based on the opinion of the local principal investigator.

          -  Active intraocular inflammation

          -  Vitreous hemorrhage in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilse Krebs, MD</last_name>
    <phone>43-17-1165</phone>
    <phone_ext>94682</phone_ext>
    <email>Ilse.Krebs@wienkav.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilse Krebs, MD</last_name>
      <phone>43-17-1165</phone>
      <phone_ext>94682</phone_ext>
      <email>Ilse.Krebs@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Ilse Krebs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>June 8, 2010</last_update_submitted>
  <last_update_submitted_qc>June 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Susanne Binder Prof</name_title>
    <organization>The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery</organization>
  </responsible_party>
  <keyword>age related macular degeneration</keyword>
  <keyword>Ranibizumab-Lucentis</keyword>
  <keyword>Bevacizumab-Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

